Ruxolitinib Phosphate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ruxolitinib Phosphate |
| DrugBank ID | DB08877 |
| Brand Names (EU) | Opzelura |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.73% |
Approved Indication (EMA)
Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | uterine corpus perivascular epithelioid cell tumor | 99.73% | DL |
| 2 | benign PEComa | 99.73% | DL |
| 3 | lymphangiomyoma | 99.72% | DL |
| 4 | lymphangioleiomyomatosis | 99.64% | DL |
| 5 | liposarcoma | 99.52% | DL |
| 6 | familial rhabdoid tumor | 99.49% | DL |
| 7 | lung PEComa | 99.44% | DL |
| 8 | ovarian myxoid liposarcoma | 99.39% | DL |
| 9 | primary myelofibrosis | 99.35% | DL |
| 10 | acquired hemophagocytic lymphohistiocytosis associated with malignant disease | 99.32% | DL |
| 11 | hemophagocytic syndrome associated with an infection | 99.32% | DL |
| 12 | thrombocytopenia | 99.30% | DL |
| 13 | dermatofibrosarcoma protuberans | 99.29% | DL |
| 14 | plasmacytoma | 99.22% | DL |
| 15 | hereditary thrombocytopenia with normal platelets | 99.15% | DL |
| 16 | marcothrombocytopenia with mitral valve insufficiency | 99.14% | DL |
| 17 | transient neonatal thrombocytopenia | 99.12% | DL |
| 18 | dense granule disease | 99.08% | DL |
| 19 | neurolymphomatosis | 98.86% | DL |
| 20 | rhabdoid tumor | 98.66% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.